Abionic attracts venture funding from leading Swiss firms
Abionic SA, a Swiss MedTech company focused on allergy diagnostics, announced today the closing of a CHF 2 million first financing round led by MedHoldings SA. Abionic is developing a portable biomedical device that has the potential to revolutionize the diagnosis of allergies.
The first financing round of Abionic was led by MedHoldings SA. MedHoldings SA is a Lausanne based Private Equity and Venture Capital investment company, focusing primarily on development and late stage Medtech ventures in Switzerland, Europe and Emerging Markets. Other investors include Polytech Ventures & Cie SCPC, Blue Ocean Ventures, Business Angels Switzerland (BAS) and Fongit Seed Invest. Several private investors also participated in this financing round.
<!--[if gte mso 9]> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="fa
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines